Q3 EPS Estimates for Oric Pharmaceuticals Lowered by Wedbush

Key Points

• Wedbush has lowered its Q3 2025 EPS estimate for Oric Pharmaceuticals to ($0.38), down from a prior estimate of ($0.36), while maintaining an "Outperform" rating with a price target of $20.00.
• Oric Pharmaceuticals reported a loss of ($0.47) EPS for the latest quarter, which was below analysts' expectations of ($0.46 EPS).
• Institutional investors hold approximately 95.05% of Oric Pharmaceuticals' stock, with significant recent activity including a 35.9% increase in holdings by Antipodes Partners Ltd.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Wedbush dropped their Q3 2025 earnings per share estimates for shares of Oric Pharmaceuticals in a note issued to investors on Tuesday, August 12th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous estimate of ($0.36). Wedbush has a "Outperform" rating and a $20.00 price target on the stock. The consensus estimate for Oric Pharmaceuticals' current full-year earnings is ($2.17) per share. Wedbush also issued estimates for Oric Pharmaceuticals' Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($1.68) EPS and FY2028 earnings at ($1.33) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01).

Several other research analysts also recently commented on the stock. Guggenheim reaffirmed a "buy" rating and issued a $18.00 price target on shares of Oric Pharmaceuticals in a research note on Wednesday, August 13th. Oppenheimer reduced their price target on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. LADENBURG THALM/SH SH began coverage on shares of Oric Pharmaceuticals in a research report on Tuesday, July 8th. They set a "buy" rating and a $15.00 target price for the company. Zacks Research raised Oric Pharmaceuticals to a "hold" rating in a research report on Tuesday, August 12th. Finally, HC Wainwright reduced their target price on Oric Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.63.

Oric Pharmaceuticals Trading Down 0.4%

Shares of NASDAQ ORIC traded down $0.04 during midday trading on Friday, hitting $9.56. The company's stock had a trading volume of 109,102 shares, compared to its average volume of 1,105,423. Oric Pharmaceuticals has a 12-month low of $3.90 and a 12-month high of $14.67. The firm has a market cap of $928.50 million, a P/E ratio of -5.06 and a beta of 1.69. The business's 50 day moving average is $10.30 and its two-hundred day moving average is $8.07.

Hedge Funds Weigh In On Oric Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its stake in shares of Oric Pharmaceuticals by 17,300.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company's stock worth $25,000 after purchasing an additional 2,422 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in Oric Pharmaceuticals by 35.9% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company's stock worth $53,000 after buying an additional 1,372 shares in the last quarter. Arizona State Retirement System acquired a new position in shares of Oric Pharmaceuticals during the first quarter valued at approximately $56,000. BNP Paribas Financial Markets acquired a new position in shares of Oric Pharmaceuticals during the fourth quarter valued at approximately $71,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Oric Pharmaceuticals during the first quarter worth approximately $102,000. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 32,466 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the sale, the chief financial officer directly owned 68,317 shares of the company's stock, valued at $717,328.50. This trade represents a 32.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Angie You acquired 26,597 shares of the stock in a transaction on Friday, June 20th. The stock was bought at an average price of $9.39 per share, for a total transaction of $249,745.83. Following the transaction, the director owned 26,597 shares in the company, valued at approximately $249,745.83. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 40,000 shares of company stock valued at $416,289 in the last quarter. Company insiders own 5.55% of the company's stock.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.